AVEO - AVEO Pharmaceuticals, Inc.
| Previous Close | 2.18 |
| Open | 2.12 |
| Bid | 2.17 x 2200 |
| Ask | 2.60 x 38500 |
| Day's Range | 2.12 - 2.18 |
| 52 Week Range | 0.63 - 4.24 |
| Volume | 792,236 |
| Avg. Volume | 1,706,262 |
| Market Cap | 332.968M |
| Beta | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.61 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.67 |
- ACCESSWIRE•3 days ago
Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
- Zacks•12 days ago
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
- GlobeNewswire•12 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within F.N.B., Comcast, IZEA, AVEO Pharmaceuticals, Matador Resources, and TEGNA — New Research Emphasizes Economic Growth
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of F.N.B. ...
- Market Exclusive•12 days ago
Here Is What Just Happened With Aveo Pharmaceuticals
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is attracting a substantial amount of attention in the biotechnology space early morning out of Europe this week, with the company moving on and update related to one of its lead development assets in the sector. Here is a look at what happened and why it is important for AVEO and […] The post Here Is What Just Happened With Aveo Pharmaceuticals appeared first on Market Exclusive.
- Motley Fool•13 days ago
Here's Why AVEO Pharmaceuticals Fell as Much as 17% Today
The company announced a delay concerning its top drug candidate.
- Business Wire•13 days ago
AVEO Reports First Quarter 2018 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
- Zacks•21 days ago
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
- Zacks•28 days ago
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
Surging implied volatility makes AVEO Pharmaceuticals (AVEO) lucrative to the option traders.
- Zacks•last month
AVEO Down 7.7% Since Earnings Report: Can It Rebound?
AVEO reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool•last monthWhy AVEO Oncology Jumped Higher Today
Investors see value after last week's decline.
- ACCESSWIRE•last month
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Neovasc
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial ...
- Zacks•2 months ago
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
- Business Wire•2 months ago
AVEO Oncology to Present at Upcoming Conferences
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
- Zacks•2 months ago
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
- Business Wire•2 months ago
AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
AVEO Oncology today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib as second-line treatment in advanced renal cell carcinoma , in the European Journal of Cancer.
- Zacks•2 months ago
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
- Associated Press•2 months ago
AVEO posts 4Q profit
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...
- Business Wire•2 months ago
AVEO Reports Full Year 2017 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the full year ended December 31, 2017 and provided a business update.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies — Discovering Underlying Factors of Influence
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•2 months ago
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
- Business Wire•2 months ago
AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m.
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Exelixis
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / U.S. markets spiked to session highs after minutes from the Fed's January meeting were released, but then dropped as yields for the 10-year Treasury note ...
- Zacks•3 months ago
AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
- ACCESSWIRE•3 months ago
Blog Exposure - AVEO Announced Positive NICE Recommendation for FOTIVDA(R) as First Line Treatment for Advanced Renal Cell Carcinoma
Stock Monitor: Bio-Techne Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on AVEO Pharma, Inc. (NASDAQ: AVEO ). If you ...
- Business Wire•3 months ago
AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma
AVEO Oncology today announced that the United Kingdom’s National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending FOTIVDA® for the first line treatment of adult patients with advanced renal cell carcinoma .
